Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2004-05-31

Study Completion Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells more sensitive to the drug. Combining gemtuzumab ozogamicin with cyclosporine may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving gemtuzumab ozogamicin together with cyclosporine works in treating older patients with relapsed acute myeloid leukemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine the efficacy of gemtuzumab ozogamicin and cyclosporine, in terms of the complete remission rate, in older patients with relapsed acute myeloid leukemia.
* Determine the toxicity and pharmacokinetics of this regimen in these patients.

Secondary

* Correlate clinical response with laboratory studies of drug susceptibility in patients treated with this regimen.

OUTLINE: Patients receive cyclosporine IV continuously over 72 hours on days 1-3 and 15-17. Eight hours after initiation of each cyclosporine infusion, patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed for survival.

PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study within 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

recurrent adult acute myeloid leukemia adult acute minimally differentiated myeloid leukemia (M0) adult acute myeloblastic leukemia without maturation (M1) adult acute myeloblastic leukemia with maturation (M2) adult acute myelomonocytic leukemia (M4) adult acute monoblastic leukemia (M5a) adult acute monocytic leukemia (M5b) adult erythroleukemia (M6a) adult pure erythroid leukemia (M6b) adult acute megakaryoblastic leukemia (M7) adult acute basophilic leukemia adult acute eosinophilic leukemia adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cyclosporine

Intervention Type DRUG

gemtuzumab ozogamicin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Morphologically confirmed acute myeloid leukemia (AML) by bone marrow aspirate

* More than 20% blasts by morphologic criteria
* Relapsed disease ≥ 3 months after prior complete remission
* Blasts CD33-positive by flow cytometry
* No primary hematologic disorder that preceded initial presentation with AML
* No documented secondary AML related to prior chemotherapy or toxin exposure
* No acute promyelocytic leukemia (FAB M3)
* Not a candidate for transplant therapy
* No active CNS leukemia

PATIENT CHARACTERISTICS:

Age

* 60 and over

Performance status

* Karnofsky 70-100%

Life expectancy

* Not specified

Hematopoietic

* WBC ≤ 30,000/mm\^3 (hydroxyurea allowed)

Hepatic

* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST or ALT ≤ 1.5 times ULN

Renal

* Creatinine ≤ 1.5 mg/dL

Other

* HIV negative
* No uncontrolled infection

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not planning hematopoietic stem cell transplantation immediately after study therapy

Chemotherapy

* See Disease Characteristics
* See Hematopoietic

Endocrine therapy

* Not specified

Radiotherapy

* Not specified

Surgery

* Not specified

Other

* More than 1 month since prior investigational agents
* No other concurrent anticancer therapy
* No administration of any of the following for 24 hours after cyclosporine administration:

* Diltiazem
* Verapamil
* Erythromycin
* Clarithromycin
* Metoclopramide
* Phenytoin
* Rifampin
* Phenobarbital
* Aminoglycosides
* Amphotericin B
* Vancomycin
* Cimetidine
* Ranitidine
* Trimethoprim/sulfamethoxazole
* Ketoconazole
* Fluconazole
* Itraconazole
* Voriconazole
* Carbamazepine

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen H. Petersdorf, MD

Role: PRINCIPAL_INVESTIGATOR

Fred Hutchinson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FHCRC-1820.00

Identifier Type: -

Identifier Source: secondary_id

CDR0000378021

Identifier Type: REGISTRY